• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us
Home / About Us / Management Team

Management Team

Celyad Oncology’s Management team consists of international experts whose talent, experience and commitment position the Company as a leader in the field of CAR T immunotherapy.

Management

Filippo Petti*

CHIEF EXECUTIVE OFFICER/CFO

Filippo Petti*

CHIEF EXECUTIVE OFFICER/CFO

Filippo Petti*

CHIEF EXECUTIVE OFFICER/CFO

Filippo Petti is Chief Executive Officer and Chief Financial Officer of the Company, and Executive Director. Prior to joining the Company, Mr. Petti worked in healthcare investment banking both at Wells Fargo Securities and William Blair & Company. Prior to his roles in investment banking, Mr. Petti spent several years in equity research covering U.S. biotechnology companies both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. focused on drug discovery and translational research, and later transitioning into corporate development with the company. Mr. Petti holds a Master of Business Administration from Cornell University, a Master of Science from St. John’s University and a Bachelor of Science from Syracuse University.

Philippe Dechamps*

CHIEF LEGAL OFFICER

Philippe Dechamps*

CHIEF LEGAL OFFICER

Philippe Dechamps*

CHIEF LEGAL OFFICER

Philippe Dechamps (representative of NandaDevi SRL), serves as Chief Legal Officer of the Company. Philippe started his legal career as an associate in Brussels with the law firm Linklaters De Bandt from 1994 to 1998. Until 2003, he then served as an Legal manager at Solvay Group to assist the company in its turnaround through several M&A operations in Europe, India and Far-East Asia. In 2003, he took over the position of Legal Director at Guidant, the United States company formerly active in the medical devices business before its acquisition by Boston Scientific and Abbott Laboratories in 2005. At Abbott, Philippe was leading the legal affairs of Abbott Vascular International outside of the United States. In 2008, Philippe joined Delhaize Group to lead the legal and government affairs in Europe and Asia, before becoming Group General Counsel and Secretary to the Board of Directors in 2015. In this position, he piloted the legal strategy to merge Delhaize Group with Royal Ahold in July 2016. Since December 2018, Philippe is also member of the Board of Directors of Petserco SA, the holding company of the Tom&Co group. Philippe holds law degrees from the Université Catholique de Louvain (UCL) and Vrije Universiteit Brussel (VUB), and a Master of Law (LL.M) from Harvard Law School.

David Gilham*

CHIEF SCIENTIFIC OFFICER

David Gilham*

CHIEF SCIENTIFIC OFFICER

David Gilham*

CHIEF SCIENTIFIC OFFICER

David Gilham, Ph.D., serves the Company as Chief Scientific Officer. Dr. Gilham obtained his Ph.D. from the University of Dundee, UK under the supervision of Professor Roland Wolf OBE working on cytochrome P4502D6 and Parkinson’s disease. In 1996, Dr. Gilham was recruited to work with Professor Robert Hawkins at the University of Bristol, UK to work on chimeric antigen receptor (CAR) T cells as a part of the Chimeric Eurocell European Programme lead by Prof Zelig Eshhar. In 1998, the group moved to the Paterson Institute for Cancer Research, University of Manchester. The group maintained a strong translational focus delivering several clinical trials of CAR T (including the first such trial to be initiated in the UK) while developing a strong basic research core activity including the ATTACK European Programme that drew together colleagues working in T cell therapy across Europe. Along with achieving academic independence and promotion to Senior Fellow, Dr. Gilham took over the leadership of the laboratory group in 2009. The group moved to the Institute of Cancer Sciences, University of Manchester based within the Manchester Cancer Research Centre in 2015 and Dr. Gilham was appointed Reader in 2016. In September 2016, Dr. Gilham moved to the role of Vice President at Celyad Oncology to continue working upon immune based therapies for cancer and was appointed to Chief Scientific Officer in May 2020.

Frédéric Lehmann*

VP CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

Frédéric Lehmann*

VP CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

Frédéric Lehmann*

VP CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

Frédéric Lehmann (representative of ImXense SRL), serves as Vice President Clinical Development & Medical Affairs of the Company. Dr. Lehmann is a physician by training, specialized in hematology and oncology. Dr. Lehmann has extensive experience in oncology drug development spanning early to late phase, including clinical trial design, translational research, regulatory interactions, and clinical risk management. He started his academic career at the Ludwig Institute for Cancer Research in Brussels, followed by a position at the Institute Jules Bordet. He then moved to the European Organization for Research and Treatment of Cancer (EORTC) as Medical Advisor. Dr. Lehmann began his corporate career at GlaxoSmithKline, where he led the early worldwide clinical development program for the Company’s cancer vaccines and went on to lead the research and development incubator for cancer immunotherapeutics.

Charles Morris*

Chief Medical Officer

Charles Morris*

Chief Medical Officer

Charles Morris*

Chief Medical Officer

Dr. Morris is a medical oncologist with over 20 years of oncology drug development experience in the international biotech and pharmaceutical space. Prior to joining Celyad Oncology, Dr. Morris served as Chief Medical Officer of Radius Health and held leadership positions at PsiOxus Therapeutics, ImmunoGen Inc and Allos Therapeutics, where he contributed to all phases of development for solid and hematological tumor indications, as well as life-cycle management development activities for FOLOTYN (pralatrexate) while at Allos. Before serving in these positions, he was Vice President of Worldwide Clinical Research at Cephalon, Inc., where he helped the company achieve its first oncology drug approval for Treanda® (bendamustine). He spent the early years of his career in various roles at AstraZeneca, where he significantly contributed to the worldwide development of Faslodex (fulvestrant), co-authored multiple publications regarding fulvestrant and breast cancer, and supported early clinical development activities for Iressa® (gefitinib).

Dr. Morris holds a Bachelor of Medicine, Bachelor of Surgery and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics degree from Sheffield University Medical School in the UK and is a Member of the Royal College of Physicians of London.

Philippe Nobels*

VP HUMAN RESOURCES

Philippe Nobels*

VP HUMAN RESOURCES

Philippe Nobels*

VP HUMAN RESOURCES

Philippe Nobels (representative of MC Consult SRL) serves as Vice President of Human Resources of the Company. He started his career at Price Waterhouse (now PricewaterhouseCoopers) as auditor in 1989. He also went in rotational assignment in Congo during 2 years on consulting missions for the World Bank. In 1995, he joined Fourcroy as plant controller. Then, he joined Dow Corning in 1997 where he held different positions in Finance and Human Resources. He led the HR operations in Europe, became the HR manager for Dow Corning in Belgium, and HR Business Partner for the sales and marketing functions globally. As a member of the sales and marketing Leadership teams, he contributed to Dow Corning’s major transformation initiatives to increase organizational effectiveness, employees’ engagement & performance as well as Business results. Mr. Nobels holds a Master’s Degree in Economics from the University of Namur.

Thomas Lequertier

Head of Cell Therapy Manufacturing Unit

Thomas Lequertier

Head of Cell Therapy Manufacturing Unit

Thomas Lequertier

Head of Cell Therapy Manufacturing Unit

Thomas Lequertier joined Celyad Oncology in March 2018 as Production Director, and was appointed Head of Cell Therapy Manufacturing Unit in October 2020. Prior to joining the Company, Thomas worked 13 years at Dow Corning where he held several positions of increasing responsibility within manufacturing and process engineering functions. During Thomas’ time at Dow Corning, he led manufacturing operations in Belgium and acquired expertise in building and upgrading production units. He also managed development and transfers of manufacturing processes globally. In his last role, he was in charge of defining and driving the implementation of continuous improvement projects across production sites in EU, US and Asia. Thomas holds a master degree in Bioengineering from the Université Libre de Bruxelles.

*Executive Committee Member

Board Of Directors

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use